Shanghai, December 24th, 2025 -- Luye Pharma Group announced that it has entered into an agreement with Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa) granting the latter the exclusive rights to commercialize Rykindo (risperidone microspheres for injection (Ⅱ)), Ruibailai (paliperidone palmitate injection (Ⅱ)), and Meibirui (paliperidone palmitate injection) in the Chinese Mainland. These three long-acting injectable (LAI) antipsychotics are indicated for the treatment of schizophrenia.
Under the agreement, Nhwa will be exclusively responsible for the distribution and commercialization of Rykindo, Ruibailai, and Meibirui in the Chinese Mainland, with Luye Pharma retaining ownership of the products’ assets, marketing authorizations, and all related intellectual property rights while remaining responsible for their manufacture and supply. The term of the agreement is ten years. Upon the signing of the agreement, Nhwa will pay a one-time, non-refundable licensing fee of USD 20 million to Luye Pharma. This collaboration marks the alliance of two leading players in China’s central nervous system (CNS) therapeutic field to deepen their presence in the schizophrenia treatment market and provide patients with more comprehensive treatment options.
Schizophrenia is a chronic disease with high rates of relapse and disability. Relapse due to treatment interruption or self-directed dose reduction, even progressing to treatment-resistant schizophrenia, is a major challenge in the current treatment of the disease. Compared with oral formulations, LAI antipsychotics can significantly improve treatment adherence and represent an important strategy for relapse prevention . In China, there are approximately 8 million individuals living with schizophrenia, and community healthcare institutions play a primary role in providing consolidation and maintenance treatment.
Rykindo, Ruibailai, and Meibirui were developed by Luye Pharma using its Long-Acting and Extended-Release Platform. Rykindo contains risperidone and is China’s first domestically developed, innovative second-generation LAI antipsychotic. Both Ruibailai and Meibirui contain paliperidone palmitate. Ruibailai is the world’s first and only once-monthly LAI paliperidone with an initiation regimen requiring just one injection in the first month.
Ou Silang, Executive Director of Luye Pharma (China) Management Committee, said: “Our three LAIs form a differentiated portfolio that addresses the treatment needs across all stages of schizophrenia care and has significant clinical value. CNS is one of our core strategic areas. We have built one of the most competitive CNS portfolios in China, supported by our strong platform capabilities. By collaborating to leverage complementary strengths, we can accelerate value creation across our pipeline and better address unmet clinical needs, while further prioritizing innovation and global expansion. The strategic partnership with Nhwa will enable us to strengthen our presence in the CNS market together, particularly by expanding product access in primary-level healthcare institutions, helping more patients receive standardized treatment and reducing disease burden.”
Nhwa is a leading specialty pharmaceutical company in China with a strong focus on the CNS field. It is dedicated to building comprehensive, integrated solutions for the treatment of psychiatric and neurological disorders while fostering an end-to-end ecosystem for the diagnosis and treatment of CNS diseases. In addition to its broad CNS portfolio, Nhwa has established a large, specialized commercial organization of more than 2,000 professionals and a nationwide commercialization network covering over 10,000 hospitals across China. Through this extensive infrastructure, Nhwa delivers its psychiatric and neurological products to mental health institutions at all levels, primary-level healthcare institutions, private hospitals, online pharmacies, and retail pharmacy chains.
Sun Jiaquan, President of Nhwa, said: “We are pleased to enter into this strategic partnership with Luye Pharma. Both companies have deep expertise in CNS therapeutics and share a highly aligned strategic vision. Luye Pharma’s three LAIs are highly complementary to our existing portfolio and will reinforce our position in the treatment of schizophrenia. Leveraging our nationwide commercialization system, we will work closely with Luye Pharma to support broad patient access to these therapies and provide more comprehensive and convenient treatment options.”
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to developing, manufacturing, and selling innovative medications. With R&D centers in China, the U.S., and Europe, the company is an international leader in novel drug delivery systems such as microspheres, liposomes, and transdermal patches. It also has multiple innovative products under development in two categories: new chemical entities and antibodies. From 2021 to 2025, the company has had a total of 15 new drugs approved for marketing in one or multiple countries such as the U.S., several European countries, Japan, and China.
Luye Pharma has 8 manufacturing facilities worldwide, which follow internationally accepted, GMP-compliant quality management and control systems. To date, the company has launched over 30 products in the central nervous system, oncology, cardiovascular, and other therapeutic areas. It conducts business in over 80 countries and regions, including major pharmaceutical markets such as China, the U.S., Europe, and Japan, as well as fast-growing emerging markets.
About Nhwa
Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa), founded in 1978, is a leading CNS-focused pharmaceutical company in China. Over the past 40 years, Nhwa has been dedicated to developing an innovative and differentiated pipeline covering therapeutic areas of anesthesia, analgesia, psychiatry, and neurology through in-house R&D and global partnerships.
As a fully integrated pharmaceutical company with more than 5,000 employees, Nhwa has comprehensive capabilities in drug discovery, clinical development, manufacturing, and commercialization of CNS drugs. In recent years, Nhwa has further strengthened its CNS leadership in China by providing the precision diagnosis of CNS disorders (Shanghai N-yuen Biotechnology Company) and co-founding the largest Chinese CNS Internet health platform (Happy Mood).
Shanghai, December 24th, 2025 -- Luye Pharma Group announced that it has entered into an agreement with Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa) granting the latter the exclusive rights to commercialize Rykindo (risperidone microspheres for injection (Ⅱ)), Ruibailai (paliperidone palmitate injection (Ⅱ)), and Meibirui (paliperidone palmitate injection) in the Chinese Mainland. These three long-acting injectable (LAI) antipsychotics are indicated for the treatment of schizophrenia.
Under the agreement, Nhwa will be exclusively responsible for the distribution and commercialization of Rykindo, Ruibailai, and Meibirui in the Chinese Mainland, with Luye Pharma retaining ownership of the products’ assets, marketing authorizations, and all related intellectual property rights while remaining responsible for their manufacture and supply. The term of the agreement is ten years. Upon the signing of the agreement, Nhwa will pay a one-time, non-refundable licensing fee of USD 20 million to Luye Pharma. This collaboration marks the alliance of two leading players in China’s central nervous system (CNS) therapeutic field to deepen their presence in the schizophrenia treatment market and provide patients with more comprehensive treatment options.
Schizophrenia is a chronic disease with high rates of relapse and disability. Relapse due to treatment interruption or self-directed dose reduction, even progressing to treatment-resistant schizophrenia, is a major challenge in the current treatment of the disease. Compared with oral formulations, LAI antipsychotics can significantly improve treatment adherence and represent an important strategy for relapse prevention . In China, there are approximately 8 million individuals living with schizophrenia, and community healthcare institutions play a primary role in providing consolidation and maintenance treatment.
Rykindo, Ruibailai, and Meibirui were developed by Luye Pharma using its Long-Acting and Extended-Release Platform. Rykindo contains risperidone and is China’s first domestically developed, innovative second-generation LAI antipsychotic. Both Ruibailai and Meibirui contain paliperidone palmitate. Ruibailai is the world’s first and only once-monthly LAI paliperidone with an initiation regimen requiring just one injection in the first month.
Ou Silang, Executive Director of Luye Pharma (China) Management Committee, said: “Our three LAIs form a differentiated portfolio that addresses the treatment needs across all stages of schizophrenia care and has significant clinical value. CNS is one of our core strategic areas. We have built one of the most competitive CNS portfolios in China, supported by our strong platform capabilities. By collaborating to leverage complementary strengths, we can accelerate value creation across our pipeline and better address unmet clinical needs, while further prioritizing innovation and global expansion. The strategic partnership with Nhwa will enable us to strengthen our presence in the CNS market together, particularly by expanding product access in primary-level healthcare institutions, helping more patients receive standardized treatment and reducing disease burden.”
Nhwa is a leading specialty pharmaceutical company in China with a strong focus on the CNS field. It is dedicated to building comprehensive, integrated solutions for the treatment of psychiatric and neurological disorders while fostering an end-to-end ecosystem for the diagnosis and treatment of CNS diseases. In addition to its broad CNS portfolio, Nhwa has established a large, specialized commercial organization of more than 2,000 professionals and a nationwide commercialization network covering over 10,000 hospitals across China. Through this extensive infrastructure, Nhwa delivers its psychiatric and neurological products to mental health institutions at all levels, primary-level healthcare institutions, private hospitals, online pharmacies, and retail pharmacy chains.
Sun Jiaquan, President of Nhwa, said: “We are pleased to enter into this strategic partnership with Luye Pharma. Both companies have deep expertise in CNS therapeutics and share a highly aligned strategic vision. Luye Pharma’s three LAIs are highly complementary to our existing portfolio and will reinforce our position in the treatment of schizophrenia. Leveraging our nationwide commercialization system, we will work closely with Luye Pharma to support broad patient access to these therapies and provide more comprehensive and convenient treatment options.”
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to developing, manufacturing, and selling innovative medications. With R&D centers in China, the U.S., and Europe, the company is an international leader in novel drug delivery systems such as microspheres, liposomes, and transdermal patches. It also has multiple innovative products under development in two categories: new chemical entities and antibodies. From 2021 to 2025, the company has had a total of 15 new drugs approved for marketing in one or multiple countries such as the U.S., several European countries, Japan, and China.
Luye Pharma has 8 manufacturing facilities worldwide, which follow internationally accepted, GMP-compliant quality management and control systems. To date, the company has launched over 30 products in the central nervous system, oncology, cardiovascular, and other therapeutic areas. It conducts business in over 80 countries and regions, including major pharmaceutical markets such as China, the U.S., Europe, and Japan, as well as fast-growing emerging markets.
About Nhwa
Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa), founded in 1978, is a leading CNS-focused pharmaceutical company in China. Over the past 40 years, Nhwa has been dedicated to developing an innovative and differentiated pipeline covering therapeutic areas of anesthesia, analgesia, psychiatry, and neurology through in-house R&D and global partnerships.
As a fully integrated pharmaceutical company with more than 5,000 employees, Nhwa has comprehensive capabilities in drug discovery, clinical development, manufacturing, and commercialization of CNS drugs. In recent years, Nhwa has further strengthened its CNS leadership in China by providing the precision diagnosis of CNS disorders (Shanghai N-yuen Biotechnology Company) and co-founding the largest Chinese CNS Internet health platform (Happy Mood).
